Florida Cancer Specialists & Research Institute Case Study Demonstrates Value of Genomic Testing To Improve Treatment and Outcomes For Patients With Inherited Cancers

FORT MYERS, Fla., Dec. 6, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) hematologist and medical oncologist Mahdi Taha, DO, FACOI, FACP is lead author of a case report abstract published in Annals of Case Reports that highlights the vital role of genomic testing in diagnosing and treatment of inherited types of cancer. The abstract, "Clinical Utility of Comprehensive Genomic Profiling in a Rare Case of Metachronous Endometrial and Colorectal Primary Cancers," illustrates the complexities in diagnosing inherited cancers associated with Lynch Syndrome (LS) and the pivotal role of comprehensive genomic testing to inform diagnosis and guide treatment tailored to the unique genetic makeup of each patient.

LS is associated with an increased risk of inherited colorectal, endometrial and other cancers. In the U.S., LS is estimated to affect as many as 1 in 300 people, resulting in a 70 to 80 percent increased risk of developing certain cancers.

In the abstract, the authors note: "Early detection and precise treatment strategies, informed by genomic insights, are essential for improving outcomes in patients with Lynch Syndrome, especially in those with atypical presentations or limited family history."

Dr. Taha said, "This milestone reflects the collaborative efforts and dedication to advancing cancer care that FCS has continuously supported. Our extensive next-generation testing capabilities and clinical research focus continue to positively impact patient outcomes."

The abstract details the case of a 34-year-old female with stage IVb metastatic endometrial cancer complicated by colon cancer who is is currently being treated with targeted immunotherapy with positive results.

FCS offers an extensive menu of genomic testing at its clinics statewide to detect oncogenic mutations in hundreds of different genes simultaneously, enabling clinicians to make faster diagnoses of a wide range of cancers while providing recommendations for clinical trials options and personalized therapies based on each patient's results.

"This case report represents a significant step forward in our understanding of the importance of genomic testing in treating cancer, highlighting the power of collaboration and innovation in advancing patient care," said FCS Assistant Managing Physician David Wenk, MD. "We are proud to see FCS and its physicians leading this important work and contributing to the body of evidence that guides our practice and improves outcomes for patients worldwide."

The study will be available in the printed Annals of Case Reports Volume 09, Issue 06 publication.

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)

Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with FCS participation.* Recognized for our research, FCS is a recipient of the national Clinical Trials Participation Award presented by the American Society of Clinical Oncology (ASCO). FCS physicians, trained in prestigious medical schools and research institutes, are consistently ranked nationally as Top Doctors by U.S. News & World Report.

Celebrating its 40th year in 2024, FCS has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies genomic-based treatment and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.

*Prior to approval

SOURCE Florida Cancer Specialists & Research Institute